AHR and neoplasm: To address whether dietary AhR agonists modulate the efficacy of checkpoint blockade therapy, we used fibrosarcoma tumor cells expressing the model antigen Ovalbumin (MCA101-OVA), and assessed tumor growth in mice treated or not with anti-PD1.